Riverbridge Partners LLC Sells 14,387 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Riverbridge Partners LLC cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 260,595 shares of the medical research company's stock after selling 14,387 shares during the period. Riverbridge Partners LLC owned about 0.51% of Charles River Laboratories International worth $61,605,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. AMG National Trust Bank bought a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $1,119,000. Trexquant Investment LP acquired a new position in Charles River Laboratories International during the 3rd quarter worth $4,104,000. CGN Advisors LLC acquired a new position in Charles River Laboratories International during the 4th quarter worth $1,663,000. AQR Capital Management LLC lifted its holdings in Charles River Laboratories International by 29.6% during the 3rd quarter. AQR Capital Management LLC now owns 84,616 shares of the medical research company's stock worth $16,583,000 after buying an additional 19,347 shares in the last quarter. Finally, Gateway Investment Advisers LLC lifted its holdings in Charles River Laboratories International by 17.8% during the 4th quarter. Gateway Investment Advisers LLC now owns 1,480 shares of the medical research company's stock worth $350,000 after buying an additional 224 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on CRL shares. Argus upped their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, March 18th. Robert W. Baird upped their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an "outperform" rating in a report on Thursday, February 15th. Guggenheim downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Finally, Citigroup increased their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.23.

Charles River Laboratories International Trading Down 3.3 %

Shares of CRL traded down $8.65 during trading hours on Thursday, reaching $250.66. The stock had a trading volume of 684,723 shares, compared to its average volume of 565,949. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The firm has a 50-day moving average of $249.07 and a 200 day moving average of $218.03. The company has a market cap of $12.91 billion, a P/E ratio of 27.22, a P/E/G ratio of 2.05 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, beating analysts' consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $991.25 million. During the same quarter in the prior year, the company earned $2.98 EPS. The firm's quarterly revenue was down 7.9% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 in the last quarter. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.